Bavarian Nordic says first milestone payment under new J&J deal could be in 2019

COPENHAGEN (Reuters) - Danish biotech company Bavarian Nordic expects to get a first milestone payment under a new deal with Janssen Pharmaceuticals in 2019, if clinical trials for vaccines targeting hepatitis B and HIV-1 get underway next year, a company executive said.